Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.
@article{MosesKolko2005NeonatalSA, title={Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.}, author={Eydie L. Moses-Kolko and Debra L Bogen and James M. Perel and Amy Bregar and Kathleen Uhl and Bob Levin and Katherine L. Wisner}, journal={JAMA}, year={2005}, volume={293 19}, pages={ 2372-83 } }
CONTEXT
A neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI) exposure during the last trimester of pregnancy has been identified. The US Food and Drug Administration (FDA) and drug manufacturers have recently agreed to a class labeling change for SRIs, which include selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), to include information about potential adverse events in neonates exposed in utero…
392 Citations
In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Evidence for Poor Neonatal Adaptation
- Medicine, Psychology
- 2008
This article will critically evaluate the literature regarding perinatal outcomes for infants exposed to SSRI/SNRIs in utero, suggesting practice implications for nursing, medical care, and family education and support for those exposed.
Serotonin Reuptake Inhibitor-Induced Perinatal Complications
- Medicine, PsychologyPaediatric drugs
- 2007
The opportunity of tapering and discontinuing SRIs in late pregnancy should be taken into consideration, although to date the evidence to support such a clinical decision is preliminary.
Neonatal Withdrawal Syndrome following Late in utero Exposure to Selective Serotonin Reuptake Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies
- MedicinePsychotherapy and Psychosomatics
- 2021
The present work provides a framework for the identification of neonatal SSRI withdrawal syndrome and suggests tapering and discontinuation of antidepressant drugs before and during the early phase of pregnancy are worth attempting to prevent the occurrence of this syndrome.
Short-Term Neonatal Outcome among Term Infants after in utero Exposure to Serotonin Reuptake Inhibitors
- MedicineNeonatology
- 2013
Despite the high incidence of clinical signs among infants born to SRI-treated mothers, most of their symptoms were mild and self-limited, and postnatal monitoring and observation is needed.
Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
- MedicineJournal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
- 2020
Selective serotonin reuptake inhibitors in pregnancy and infant outcomes.
- MedicinePaediatrics & child health
- 2011
Information is provided that should be used to make individual risk-benefit decisions when considering the treatment of depression during pregnancy, including whether or not to prescribe an SSRI.
Fetal Effects of In Utero Serotonin Reuptake Inhibitor (SRI) Antidepressant Exposure
- Psychology, Biology
- 2016
Given the paucity of empiric fetal data in humans, what is known about three postnatal findings that may reflect fetal developmental sequelae associated with in utero SRI exposure are drawn.
Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome
- MedicineTherapeutic drug monitoring
- 2012
Causality cannot be confirmed in observational study settings, however, parallel results in individual studies regarding the cardiac malformations and pulmonary hypertension of the newborn, together with an existing biologically plausible mechanism behind these events may support causality.
Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.
- Medicine, PsychologyThe Journal of clinical psychiatry
- 2017
The presence of neonatal signs at 2-4 weeks was more closely associated with prematurity than with in utero SRI or mood disorder exposure, and a significant relationship between Finnegan signs and preterm birth.
Early Morbidity and Mortality Following In Utero Exposure to Selective Serotonin Reuptake Inhibitors
- Medicine, PsychologyCNS Drugs
- 2012
The children in the SSRI group were more likely to be admitted to hospital in the first years of life, and this may reflect their prenatal exposure to SSRIs, be related to maternal depression, or SSRI use may be a proxy for an environmental exposure such as smoking, or a combination of these factors.
References
SHOWING 1-10 OF 58 REFERENCES
Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis
- Medicine, PsychologyThe Lancet
- 2005
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
- Medicine, PsychologyActa paediatrica
- 2001
Five cases of neonatal withdrawal syndrome after third trimester in utero SSRI exposure are reported, with Symptoms were irritability, constant crying, shivering, increased tonus, eating and sleeping difficulties and convulsions.
Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
- Medicine, PsychologyArchives of general psychiatry
- 2003
Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
- Medicine, PsychologyThe Journal of clinical psychiatry
- 2004
While transient neonatal symptoms were found in infants after single-agent prenatal exposure to SSRIs, the addition of clonazepam appeared to alter paroxetine metabolism, leading to increased drug levels and risk for transient Neonatal symptoms.
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
- MedicineJAMA
- 1998
The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses.
Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.
- Psychology, MedicinePediatrics
- 2004
Results provide the first systematic evidence that women who use SSRIs during pregnancy have healthy, full-birth-weight newborn infants who show disruptions in a wide range of neurobehavioral outcomes.
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
- Medicine, PsychologyThe American journal of psychiatry
- 1996
Exposure to certain psychotropic drugs in utero may increase the risk for some specific congenital anomalies, but the rate of occurrence of these anomalies even with the increased risk remains low.
Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response
- Medicine, PsychologyPediatric Research
- 2002
Prolonged prenatal SSRI exposure appears to be associated with reduced behavioral pain responses and increased parasympathetic cardiac modulation in recovery following an acute neonatal noxious event.
Perinatal outcome following third trimester exposure to paroxetine.
- Medicine, PsychologyArchives of pediatrics & adolescent medicine
- 2002
When used near term, paroxetine is associated with a high rate of neonatal complications, possibly caused by its common discontinuation syndrome.
Effects of third trimester fluoxetine exposure on the newborn.
- Medicine, PsychologyJournal of clinical psychopharmacology
- 1995
It is unlikely that maternal fluoxetine use during the third trimester results in significant postnatal complications, and reported rates from the National Hospital Discharge Survey are likely to be low.